Qdrant, a provider of vector search technology, announced that its Qdrant Cloud infrastructure powers Sapu's AI research platform, which indexes and queries all 28 million PubMed abstracts in a single searchable collection. This capability is designed to accelerate biomedical discovery workflows for Sapu, an early-stage biopharmaceutical company developing treatments for hard-to-treat cancers.
According to a blog post by Daniel Azoulai, Sapu's AI platform evolved from an early prototype into a production-scale system that supports scientific literature review, standard operating procedure retrieval, and AI-assisted research authorship. The platform has already contributed to seven peer-reviewed research papers and is used broadly across Sapu's research operations.
The implications of this development are significant for the pharmaceutical industry and cancer research. By enabling rapid access to the vast repository of PubMed abstracts, researchers can more efficiently identify relevant studies, understand treatment mechanisms, and design experiments. This could potentially shorten the timeline for drug discovery and bring new therapies to patients faster.
Sapu is expanding the platform's capabilities through a robotics partnership with Techforce and evaluating edge deployments for secure, air-gapped laboratory environments. These next-stage applications rely on Qdrant's hybrid vector and metadata retrieval architecture, which provides the scale, speed, and flexibility required.
Qdrant's technology is built in Rust and has surpassed 250 million downloads, earned more than 29,000 GitHub stars, and grown to a global team of over 100 employees across more than 20 countries. The company offers both open-source and managed cloud vector search solutions, giving developers precise control over indexing, search, and retrieval of high-dimensional data.
For more information, click here.
